MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.lanepe.2024.101092

Медицинская библиотека · The Lancet regional health. Europe · 2024

Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.

Weiß Claudia, Becker Lena-Luise, Friese Johannes, Blaschek Astrid, Hahn Andreas, Illsinger Sabine, Schwartz Oliver, Bernert Günther, Hagen Maja von der, Husain Ralf A, Goldhahn Klaus, Kirschner Janbernd, Pechmann Astrid, Flotats-Bastardas Marina, Schreiber Gudrun, Schara Ulrike, Plecko Barbara, Trollmann Regina, Horber Veronka, Wilichowski Ekkehard, Baumann Matthias, Klein Andrea, Eisenkölbl Astrid, Köhler Cornelia, Stettner Georg M, Cirak Sebahattin, Hasselmann Oswald, Kaindl Angela M, Garbade Sven F, Johannsen Jessika, Ziegler Andreas, SMArtCARE and Swiss-Reg-NMD study group

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Real-world data on gene addition therapy (GAT) with onasemnogene abeparvovec (OA), including all age groups and with or without symptoms of the disease before treatment are needed to provide families with evidence-based advice and realistic therapeutic goals. Aim of this study is therefore a population-based analysis of all patients with SMA treated with OA across Germany, Austria and Switzerland (D-A-CH).

METHODS

This observational study included individuals with Spinal Muscular Atrophy (SMA) treated with OA in 29 specialized neuromuscular centers in the D-A-CH-region. A standardized data set including WHO gross motor milestones, SMA validated motor assessments, need for nutritional and respiratory support, and adverse events was collected using the SMArtCARE registry and the Swiss-Reg-NMD. Outcome data were analyzed using a prespecified statistical analysis plan including potential predictors such as age at GAT, SMN2 copy number, past treatment, and symptom status.

FINDINGS: 343 individuals with SMA (46% male, 54% female) with a mean age at OA of 14.0 months (range 0-90, IQR 20.0 months) were included in the analysis. 79 (23%) patients were clinically presymptomatic at the time of treatment. 172 (50%) patients received SMN2 splice-modifying drugs prior to GAT (risdiplam: n = 16, nusinersen: n = 154, both: n = 2). Functional motor improvement correlated with lower age at GAT, with the best motor outcome in those younger than 6 weeks, carrying 3 SMN2 copies, and being clinically presymptomatic at time of treatment. The likelihood of requiring ventilation or nutritional support showed a significantly increase with older age at the time of GAT and remained stable thereafter. Pre-treatment had no effect on disease trajectories. Liver-related adverse events occurred significantly less frequently up to 8 months of age. All other adverse events showed an even distribution across all age and weight groups.

INTERPRETATION: Overall, motor, respiratory, and nutritional outcome were dependent on timing of GAT and initial symptom status. It was best in presymptomatic children treated within the first six weeks of life, but functional motor scores also increased significantly after treatment in all age groups up to 24 months. Additionally, OA was best tolerated when administered at a young age. Our study therefore highlights the need for SMA newborn screening and immediate treatment to achieve the best possible benefit-risk ratio.

FUNDING: The SMArtCARE and Swiss-Reg-NMD registries are funded by different sources (see acknowledgements).

Для цитирования: Weiß Claudia, Becker Lena-Luise, Friese Johannes, Blaschek Astrid, Hahn Andreas, Illsinger Sabine, Schwartz Oliver, Bernert Günther, Hagen Maja von der, Husain Ralf A, Goldhahn Klaus, Kirschner Janbernd, Pechmann Astrid, Flotats-Bastardas Marina, Schreiber Gudrun, Schara Ulrike, Plecko Barbara, Trollmann Regina, Horber Veronka, Wilichowski Ekkehard, Baumann Matthias, Klein Andrea, Eisenkölbl Astrid, Köhler Cornelia, Stettner Georg M, Cirak Sebahattin, Hasselmann Oswald, Kaindl Angela M, Garbade Sven F, Johannsen Jessika, Ziegler Andreas, SMArtCARE and Swiss-Reg-NMD study group. Efficacy and safety of gene therapy with onasemnogene abeparvovec in children with spinal muscular atrophy in the D-A-CH-region: a population-based observational study.. The Lancet regional health. Europe. 2024. DOI: 10.1016/j.lanepe.2024.101092.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.